Bladder Cancer - Results from #800

REVIEW UroToday

Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress October 12, 2023

Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer. October 12, 2023

Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). October 12, 2023

The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial. October 11, 2023

Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study. October 11, 2023

New Health Economic Analysis in France Concludes There Is Insignificant Cost Difference Between White Light and Blue Light Cystoscopy Use When Applying ccAFU Guidelines October 10, 2023

Bladder cancer patient and provider perspectives on smoking cessation. October 10, 2023

Immunotherapy for advanced or metastatic urothelial carcinoma. October 10, 2023

VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. October 10, 2023

A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix® in patients diagnosed with non-muscle-invasive bladder cancer in France. October 10, 2023

Does the urinary microbiome profile change after treatment of bladder cancer? October 9, 2023

Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific. October 9, 2023

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. October 6, 2023

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma. October 6, 2023

Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. October 5, 2023

Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy. October 5, 2023

Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. October 5, 2023

Trial in Progress: Adaptive RADiation Therapy with Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients with MIBC (RAD-SG). October 4, 2023

Real World Multi-Institutional Outcomes of Bladder Carbogen and Nicotinamide (BCON) in Muscle-Invasive Bladder Cancer (MIBC). October 4, 2023

2023 ASCO genitourinary cancers symposium: a focus on urothelial carcinoma. October 3, 2023

Page 41 of 517